Cardiology

Pharmaceutical company comments on results of coronary artery disease study

Published in Medical Letter on the CDC and FDA, December 12th, 2004

King Pharmaceuticals reported that data from the Prevention of Events with Angiotensin-Converting-Enzyme Inhibitors (PEACE) trial released at the recent American Heart Association meeting failed to demonstrate that trandolapril confers a therapeutic benefit for patients with stable coronary artery disease or slightly reduced left ventricular function.

PEACE is a large-scale, randomized, placebo-controlled clinical trial that evaluated the benefits of adding angiotensin-converting-enzyme (ACE) inhibitor trandolapril 4 mg to modern conventional therapy.

King also said that conversely, data from the Heart Outcomes Prevention Evaluation (HOPE) trial,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-12-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry